GLOW & KLOWProtocols for Anti-Aging & Skin Health

GLOW and KLOW are pre-mixed peptide blends combining GHK-Cu (tissue remodeling), BPC-157 (new blood vessel formation and barrier repair), and TB-500 (cell migration) into a single injection protocol for skin rejuvenation. KLOW adds KPV for dedicated inflammation suppression in reactive or sensitized skin.

The difference: GLOW rebuilds the structural scaffold — collagen, elastin, the connective matrix that determines firmness and texture. KLOW does the same work while calming the immune overactivity that makes rosacea, post-procedure redness, and reactive skin worse before it gets better.

Where these protocols differ from topical skincare: they target the dermal matrix from below, addressing structural loss that no surface-applied product can reach. Texture shifts within 2–4 weeks, fine lines soften by weeks 4–8, and firmer structure with scar changes arrives by weeks 8–12.

Jump to protocol →

GLOW or KLOW: Which one is right for you?

GLOW — best for: aging skin, fine lines, firmness loss, scar improvement, hair growth support, general skin quality.

KLOW — best for: reactive or redness-prone skin, active rosacea or inflammatory acne, post-procedure recovery (laser, microneedling), chronic low-grade facial inflammation.

Not sure? Start with GLOW — switch to KLOW if inflammation limits results. You can alternate between them based on skin condition. Some practitioners use KLOW during active flares and GLOW during stable periods.

What's in Each Vial

GLOW

KLOW

The 50/10/10 Ratio

GHK-Cu dominates because collagen production is the continuous demand throughout the protocol. BPC-157 and TB-4 are precision signals — they establish infrastructure and coordinate migration at lower doses. The ratio is designed for cosmetic applications, not injury recovery. (For injury-appropriate dosing, see the GLOW/KLOW for Injuries guide.)

Reconstitution & Dosing

GLOW Vial

KLOW Vial

See the Reconstitution Guide for technique. The peptide dosing calculator can verify injection volumes.

How They Work

Tissue repair proceeds through overlapping phases: inflammation control, barrier stabilization, cell migration, and matrix remodeling. Each component in these blends aligns with a different phase.

GHK-Cu — The Architect

A copper-binding tripeptide that switches on over 4,000 genes involved in tissue repair — collagen production, antioxidant defense, wound healing — while switching off genes linked to inflammation and tissue breakdown¹. Circulating levels decline with age: roughly 200 ug/mL at age 20, dropping to 80 ug/mL by age 60¹.

GHK-Cu's ability to clear damaged tissue and build quality replacement simultaneously is its distinguishing feature — it doesn't just add collagen on top of what's broken. It remodels what's there while laying down new structure.

BPC-157 — The Infrastructure Builder

A 15-amino-acid fragment from gastric juice that stabilizes tissue barriers and establishes the blood vessel network needed for active regeneration².

BPC-157 creates the blood vessel network that GHK-Cu's collagen machinery needs². Without blood flow reaching the treatment area, collagen synthesis has raw materials but no delivery system.

TB-4 — The Organizer

Full-length thymosin beta-4 (43 amino acids) — the protein that controls how repair cells move and organize within tissue³. TB-4 determines whether healing is coordinated or chaotic.

Why TB-4, not TB-500: These blends use full-length TB-4, not the TB-500 fragment (amino acids 17-23). The systemic thymosin beta-4 data — dermal, ophthalmic, cardiac models — all use the full peptide³ ⁶. TB-4 is preferred for cosmetic and systemic regeneration. The TB-500 fragment is reserved for acute, localized injury repair in separate protocols. Most commercially sold "TB-500" is actually full-length TB-4 regardless of label.

KPV — The Inflammation Switch

A three-amino-acid fragment of alpha-MSH (a natural anti-inflammatory hormone)⁴. KPV prevents inflammatory genes from activating in the first place — a more targeted approach than NSAIDs, which block inflammation after it's already started. Normal immune signaling needed for healing stays intact⁴.

Route caveat: KPV's strongest preclinical evidence is for oral delivery to gut tissue, where inflamed intestinal cells actively absorb it via the PepT1 transporter (upregulated during inflammation)⁵. Subcutaneous delivery, as in KLOW, bypasses this targeted pathway and distributes KPV systemically.

Systemic anti-inflammatory effects at injectable doses remain less characterized than oral or topical routes. The dermatological profile is supported by mechanistic data (NF-κB inhibition, immune cell stabilization) and clinical experience, but controlled human trials for SubQ KPV specifically have not been published.

The Synergy

Each compound approaches tissue quality from a different angle. Together they create conditions where repair proceeds as an organized cascade rather than isolated signals competing for resources:

• BPC-157 + TB-4: Vascular infrastructure meets organized cell migration — repair cells have roads AND directions
• GHK-Cu + TB-4: Mobilized repair cells (fibroblasts) receive genetic instructions for quality collagen — not just more collagen, but better collagen
• GHK-Cu + BPC-157: Collagen synthesis has continuous nutrient delivery via new microvascular networks
• KPV + all three (KLOW): Inflammatory noise suppressed so the entire cascade operates without interference

All three base compounds also reduce inflammation through their own mechanisms — GHK-Cu suppresses inflammatory genes, BPC-157 quiets inflammatory signaling, TB-4 shifts immune cells toward repair. KLOW's KPV adds a dedicated, targeted layer on top of this inherent capacity.

Three-Phase Protocol

Both GLOW and KLOW use identical scheduling. The per-injection dose is always 0.15 mL (15 units). Phases adjust frequency, not the mixture.

*KPV only in KLOW formulation

Phase 1: Activation (Weeks 1-4)

Dose: 0.15 mL (15 units) subcutaneous, daily

GHK-Cu activates collagen production while its copper component enables proper structural cross-linking¹. BPC-157 builds the network of small blood vessels needed to feed active tissue². TB-4 mobilizes and organizes repair cells³. In KLOW, KPV simultaneously suppresses inflammatory interference⁴.

Expected: Skin hydration improves, tone evens, texture softens, redness decreases (particularly with KLOW).

Phase 2: Remodeling (Weeks 5-8)

Dose: 0.15 mL (15 units) subcutaneous, 5×/week

Same per-injection amounts. All compounds at peak coordinated activity.

GHK-Cu drives maximum collagen production — structural proteins, elastin for bounce-back, and the water-binding molecules that keep skin hydrated from within¹. BPC-157 maintains blood flow to active tissue². TB-4 coordinates efficient cell organization³. Small human dermatology studies report meaningful increases in collagen synthesis and reductions in wrinkle depth over 8-12 weeks¹.

Expected: Fine lines soften, elasticity improves, visible glow returns, skin thickness increases (measurable via ultrasound).

Phase 3: Maintenance (Weeks 9+)

Dose: 0.15 mL (15 units) subcutaneous, 2-3x weekly

Pulsed administration maintains regenerative signaling without overwhelming the body's regulatory balance:

• Prevents receptor downregulation — continuous exposure causes receptors to become less responsive. Pulsed dosing maintains sensitivity.
• Allows integration time — the body needs 48-72 hours between doses to organize and cross-link newly synthesized collagen. Constant stimulation can produce disorganized matrix.
• Preserves endogenous capacity — enhances rather than replaces natural repair systems. Sustainable long-term without diminishing returns.

Duration: Ongoing, or quarterly 4-week intensive cycles (return to daily dosing every 3-4 months).

Timeline: What to Expect

Administration

• Route: Subcutaneous (abdomen or thigh)
• Timing: Consistent daily timing; evening preferred (collagen synthesis peaks during deep sleep)
• Sites: Rotate to prevent irritation
• Storage: Refrigerate 2-8C after reconstitution, stable 30 days, protect from light

Supply Planning

Each vial provides 20 doses at 0.15 mL (3 mL BAC water ÷ 0.15 mL per dose):

• Weeks 1-8 (daily): 56 doses = 3 vials
• Weeks 9-12 (2-3x weekly): 8-12 doses = 1 vial
• Total: 3-4 vials for a 12-week protocol

Supporting Factors

Optional adjuncts:

• Red light therapy (630-670 nm): 10-20 min daily
• Microneedling: Every 3-4 weeks during Phase 2
• Topical GHK-Cu (0.5-1%): Non-injection days

When Progress Stalls

1. Check protein intake — collagen needs substrate
2. Check sleep quality — GHK-Cu gene expression peaks overnight
3. Verify injection technique and storage
4. Add vitamin C if not already supplementing
5. If inflammation is clearly limiting results and you're on GLOW, switch to KLOW

Safety & Contraindications

Do not use if:

• Active malignancy or cancer history <5 years (BPC-157, TB-4, and GHK-Cu promote new blood vessel formation)
• Wilson's disease or copper metabolism disorders (GHK-Cu)
• Pregnancy or breastfeeding
• Known allergy to any component

Side effects (uncommon):

• Mild injection site reactions (redness, slight swelling)
• Transient warmth or flushing (primarily from GHK-Cu)
• No known systemic side effects at therapeutic doses in available studies

Cycling recommendation: Conservative approach is 8-12 weeks active followed by 4-8 weeks rest, or transition to 2-3x weekly maintenance indefinitely. Cycling recommendations are based on theoretical concerns about sustained multi-peptide angiogenesis rather than documented adverse events.

Evidence Quality

The individual components are well-characterized, but no controlled clinical trials have evaluated either GLOW or KLOW as blended formulations in human subjects. Synergy between components is inferred from complementary mechanisms, not demonstrated in combination studies.

FAQ

Related Topics

• GHK-Cu for Skin — GHK-Cu mechanism deep-dive
• GLOW/KLOW for Injuries — Why these ratios fail for injury recovery
• BPC-157 Guide — BPC-157 standalone use
• Wolverine Stack — BPC-157 + TB-500 for injury
• NAD+ Guide — Cellular energy for recovery
• Where to Inject Peptides — Injection guide for GLOW/KLOW and individual compounds
• Reconstitution Guide — Technique for all peptide vials
• TB-500 Guide — Thymosin Beta-4 fragment used in injury protocols (distinct from TB-4 in GLOW/KLOW)

References

¹ GHK-Cu gene modulation — COL1A1/COL3A1 collagen gene activation, lysyl oxidase cross-linking, bidirectional MMP regulation, SOD/catalase antioxidant expression, 4,000+ gene modulation via microarray: Pickart L, Margolina A. Int J Mol Sci 2018. DOI: 10.3390/ijms19071987; Pickart L. J Biomater Sci Polym Ed 2008. PubMed: 18644225

² BPC-157 angiogenic signaling — VEGF expression, tight junction upregulation, capillary sprouting, microvascular network formation: Sikiric P et al. Curr Pharm Des 2018. PubMed: 29737246

³ Thymosin beta-4 tissue repair — G-actin sequestration for cell mobility, TGF-beta anti-scarring regulation, M2 macrophage polarization, endothelial anti-inflammatory effects: Goldstein AL et al. Trends Mol Med 2005. PubMed: 16099219

⁴ KPV anti-inflammatory mechanism — NF-κB inhibition, cytokine suppression, M1→M2 immune cell shift, mast cell stabilization: Luger TA, Brzoska T. Ann Rheum Dis 2007. PubMed: 17921186

⁵ KPV oral delivery — PepT1 transporter uptake in inflamed intestinal tissue, murine IBD models: Kannengiesser K et al. J Crohns Colitis 2008. PubMed: 21172189

⁶ TB-4 wound healing — dermal repair acceleration, full-length peptide in wound models: Malinda KM et al. J Invest Dermatol 1999. PubMed: 10469299